Surgery Partners Q2 revenue up 8.4% to $826.2M; Adj EBITDA $129M, up 9%; reaffirms FY2025 guidance

Surgery Partners, Inc.

2025-Q2 EPS reported -$0.32 revenue$1,602,200,000

Revenue $826.2M (+8.4% YoY); same-facility revenue +5.1%, same-facility cases +3.4%.
Adjusted EBITDA $129.0M (+9.0% YoY); net loss attributable to Surgery Partners $2.5M.
Full-year 2025 guidance reaffirmed: revenue $3.30-3.45B, Adjusted EBITDA $555-565M.
Cash $250.1M and $394.9M revolver capacity at June 30, 2025; net debt/EBITDA 4.1x.
CEO cites active evaluation of portfolio optimization to reduce leverage and accelerate cash flow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.